Purpose: The aim of this study was to evaluate the cost-effectiveness of apixaban compared with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in Japan.
ABSTRACT
Purpose: The aim of this study was to evaluate the cost-effectiveness of apixaban compared with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in Japan.
Methods: A previously published lifetime Markov model was adapted to evaluate the cost-effectiveness of apixaban compared with warfarin in patients with NVAF in Japan. In the same model, the costs associated with each clinical event and background mortality were replaced with Japanese data. Whenever available, some of the utility parameters were derived from Japanese published literature. Lifetime horizon was selected to evaluate the value of the treatment benefit (stroke prevention) against potential risks (such as major bleedings) among patients with NVAF. Direct medical cost, long-term care cost, and qualityadjusted life years (QALYs) were calculated from the payers' perspective.
Findings: Compared with warfarin, treatment with apixaban was estimated to increase life expectancy by 0.231 year or 0.240 QALYs while treatment cost increased by ¥511,692 (US $5117 at an exchange rate of US $1 ¼ ¥100). The incremental cost-effectiveness ratio was ¥2,135,743 per QALY (US $21,357 per QALY). On the basis of the results of the probabilistic sensitivity analysis, when the willingness-to-pay threshold was set at approximately Z¥2,250,000 (US $22,500) per QALY, the probability of apixaban being cost-effective was Z50%. Assuming a willingness-to-pay threshold of ¥5,000,000 (US $50,000) and ¥6,700,000 (US $67,000) in Japan, the probability of apixaban being cost-effective was 85% and 91%, respectively.
Conclusion: Although most participants in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial used for the efficacy data of apixaban in the model were non-Japanese patients, the impact of the limitations on our results was considered small, and our results were deemed robust because of the additional effect in Japanese patients compared with that in the global population according to the subanalysis of Japanese patients in the trial. Therefore, based on an adaptation of a published Markov model, apixaban is a cost-effective alternative to warfarin in Japan for stroke prevention among patients with NVAF.
INTRODUCTION
Atrial fibrillation (AF) affects 0.6% to 1.6% of the general population and up to 14% of patients in cardiovascular clinics in Japan.
1,2 AF increases the risk of stroke by nearly 5-fold. 3 Warfarin has been used to prevent the occurrence of stroke, a complication of AF. However, monitoring of the prothrombin time-international normalized ratio is necessary during warfarin use, and it is not easy to maintain the dose of the drug within the desired therapeutic range. 4 Use of warfarin can be associated with hemorrhagic adverse effects, including severe and life-threatening events, such as intracerebral hemorrhage. In addition, warfarin is complicated by challenges such as drug-drug interactions and restriction of foods, including vitamin K. Recent guidelines from the European Society of Cardiology recommend the use of novel anticoagulants (NOACs) as alternatives to warfarin or antiplatelet therapy in most AF patients who require stroke prevention. 5 Apixaban, an orally active factor Xa inhibitor, has been studied in a Phase III global randomized clinical trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARIS-TOTLE]) versus dose-adjusted warfarin in patients with nonvalvular atrial fibrillation (NVAF). The study found that the incidence of stroke and systemic embolism decreased significantly and the frequency of major bleeding also decreased significantly in the apixaban 5 mg BID group compared with the warfarin control group. 6 NOACs, such as dabigatran, rivaroxaban, and apixaban, are currently available for clinical use for the prevention of stroke in patients with NVAF in Japan. According to the 2011 Estimates of National Medical Care Expenditure report, the medical cost of cerebrovascular diseases, including ischemic and hemorrhagic stroke, was ¥1.8 trillion (US $18 billion at an exchange rate of US $1 ¼¥100), which accounted for approximately 6% of the overall medical cost (¥28 trillion [US $280 billion]). 7 Prevention of stroke is important not only clinically but also from the perspective of health economics.
High drug acquisition cost of NOACs versus warfarin in Japan warrants such analyses to be conducted from the Japanese payer perspective to inform selection of optimal anticoagulation therapy for NVAF patients. Warfarin is currently still considered the standard of care, although NOACs are becoming more widely used in Japan. 8 In this study, we evaluated the costeffectiveness of apixaban compared with warfarin based on Japanese data.
METHODS Model
In this study, a previously published model for health economic evaluation 9,10 ( Figure 1 ) was adapted to evaluate the cost-effectiveness of apixaban compared with warfarin in Japan. The model was a Markov model developed using Microsoft Excel, and a 6-week cycle length was chosen to capture the possibilities of events related to AF that occur within a short period. The detailed description of the model can be found in the publications by Dorian et al. 9 In brief, all patients started in the NVAF state, and certain portions of the cohort were assigned during each model cycle to one of the modeled 17 health states. The health states comprised NVAF, ischemic stroke (mild, moderate, severe), hemorrhagic stroke (mild, moderate, severe), recurrent ischemic stroke (mild, moderate, severe), recurrent hemorrhagic stroke (mild, moderate, severe), systemic embolism, gastrointestinal bleeding and myocardial infarction (MI), and death. Intracranial hemorrhage (ICH) that is not hemorrhagic stroke (other ICH), major bleeding other than gastrointestinal bleeding, clinically relevant nonmajor bleeding, and other cardiovascular hospitalization were also considered as events. Patients who experience these events were assumed to stay in their initially assigned anticoagulation state, and events were modeled as transient states. These assignments were based on the probability of experiencing an event that in turn was derived from secondary analyses of trial data 9 ( Tables I-IV) . Some events altered subsequent risks of modeled events, including death (eg, patients with ischemic stroke would have higher probability of death or patients experiencing MI would have greater likelihood of acute mortality). In addition, stroke severity was considered. Stroke severity was evaluated by the modified Rankin Scale (mRS) as mild (mRS scores 0-2), moderate (mRS scores 3-4), and severe (mRS score 5; an mRS score of 6 is death). Recurrence was also considered for stroke. For treatment after each event, patients were assumed to continue the first-line treatment (apixaban or warfarin) after ischemic stroke, systemic embolism, MI, clinically relevant nonmajor bleeding, and other cardiovascular hospitalization. However, for ICH (including hemorrhagic stroke), gastrointestinal bleeding, and other major bleeding, patients were assumed to discontinue or suspend first-line treatment for 6 weeks. Patients who discontinued first-line treatment were assumed to start second-line aspirin treatment. In essence, model structure was built to reflect real-life treatment paradigms and consequences of treatment decision.
Localization
In the adaptation analysis, we used parameters such as cost of each event and some of the utility parameters and background mortality using the Japanese data. The cost of the acute phase for each event were obtained from Japanese claims data for patients with AF (excluding AF associated with rheumatic mitral valve disease and mechanical valve) using the Figure 1 . Markov model. The model uses a previously published 6-week cycle model. 9, 10 All patients start with the nonvalvular atrial fibrillation (NVAF) state, and certain portions of the cohort are assigned during each model cycle to 1 of the modeled 17 health states. The health states comprise ischemic stroke (IS) (mild, moderate, severe), hemorrhagic stroke (HS) (mild, moderate, severe), recurrent IS (mild, moderate, severe), recurrent HS (mild, moderate, severe), systemic embolism, gastrointestinal bleeding and myocardial infarction (MI), or death. Other intracranial hemorrhage (ICH), major bleeding other than gastrointestinal bleeding, clinically relevant nonmajor (CRNM) bleeding, and other cardiovascular hospitalization are also considered events, but patients are assumed to stay in their initially assigned anticoagulation states and the events are modeled as transient states. Some events altered the subsequent risks of modeled events, including death. AC = anticoagulant; ASA = aspirin. M indicates Markov process, and triangles indicate that a patient transitions to the following state in the next cycle.
Medical Data Vision Co Ltd (MDV) database. The database provided claims data from 131 hospitals (as of April 2013) using the Diagnosis Procedure Combination (DPC) system for medical service claims (21% of general hospitals but 55% of general beds in Japan is under the DPC system in 2014 15 ). DPC is a reimbursement system for hospitals to claim a treatment cost comprehensively estimated for one hospitalization per patient. The actual costs per event from admission until discharge (including death; ie, mRS score of 6) with a name of each event in the record of "disease name with the most health resources invested" in DPC data were used to estimate costs associated with the acute phase of each event. The definitions of the target population and events are given in Table V .
The costs of chronic stroke were obtained from the study by Hattori et al, which included not only direct medical cost but also the long-term care cost. 16 The cardiogenic brain embolism data derived from Stroke Data Bank 2009 were used for distribution of the mRS scores for each stroke severity in Japanese patients. 17 The cost of medication therapy and that of percutaneous coronary intervention for the chronic phase of MI are quoted from the report of Tanihata et al. 18 The percentage of patients receiving each treatment was obtained from a study using claims data analysis in Japan by Evans et al. 19 Because the research by Tanihata et al was conducted in 2001, the cost derived from the study was adjusted to 2014 rates based on the revised total medical treatment fees thereafter (Tables VI and VII) . Japanese utility data were used only for chronicphase stroke, for which Japanese evidence is available 16 ( Table VIII) . Background mortality was set based on the 2012 Abridged Life Table according to age and sex in Japan. 20 
Analyses
Lifetime horizon was chosen to evaluate the treatment value of the preventive effect against events such as stroke in NVAF patients. The direct medical cost, long-term care cost, and qualityadjusted life-years (QALYs) were calculated from the payers' perspective. The number of events avoided per 1,000 patients with NVAF during the lifetime horizon was also evaluated. An annual discount of 2% was applied to both the cost and effectiveness in accordance with a Japanese guideline for health economic analysis. 21 In this study, the cost-effectiveness of apixaban compared with warfarin was estimated in base case analysis. One-way sensitivity analysis for each parameter was conducted to confirm the impact of each parameter on the analysis results with the 95% CI for each parameter. In addition, probabilistic sensitivity analysis by Monte-Carlo simulation with 2000 iterations was performed, and parameter uncertainty was assessed by the cost-effectiveness acceptability curve, which plotted the probability that apixaban is cost-effective in willingness to pay (WTP) on the horizontal axis.
RESULTS

Base Case Analysis
The simulation results in NVAF patients treated with apixaban versus warfarin were projected to reduce the number of strokes by 16 per 1000 patients (2 for ischemic stroke and 14 for hemorrhagic stroke) and the number of bleeding episodes other than hemorrhagic stroke onset by 72 per 1000 patients. The expected life-years accrued during lifetime treatment per patient were 10.285 years for the warfarin (Table IX) .
Sensitivity Analysis
The results of the 1-way sensitivity analysis identified the following factors as having a large impact on the ICER: the risk of ischemic and unspecified stroke associated with the use of apixaban and the risk of ICH associated with the use of warfarin (Figure 2) . The range of ICER in sensitivity analysis of these parameters were ¥987,444 to ¥5,116,598 per QALY (US $9,874 to $51,166 per QALY) for risk of ischemic and unspecified stroke for apixaban and ¥832,334 to ¥3,819,575 per QALY (US $8323 to 38,196 per QALY) for risk of ICH for warfarin. In the probabilistic sensitivity analysis, the cost-effectiveness plane (scatterplot) suggested apixaban was more effective and more costly than warfarin (Figure 3) . The cost-effectiveness acceptability curve revealed that when the WTP was approximately Z¥2,250,000 (US $22,500) per QALY; the probability of apixaban being cost-effectiveness was Z50% (Figure 4) .
DISCUSSION
In this analysis, the cost-effectiveness of apixaban compared with warfarin in Japan was estimated by using Japanese data applied into a previously published model. 9, 10 Compared with warfarin, treatment with apixaban earned life-years gained of 0.231 and QALYs gained of 0.240. The original study by Dorian et al reported that discounted life-years and QALYs gain were much the same (mainly due to the mortality from the most frequent event of ischemic stroke in the apixaban arm, which was slightly higher than that in warfarin arm [18% vs 15%]). Furthermore, the utility values of severe stroke in the Japanese model were significantly lower than those in the original model, which increased the gain in QALYs from stroke severity improvement by apixaban. These findings could be attributed as the cause of our results that the gain in QALYs was higher than the gain in life-years. Higher gain in QALYs by treatment with apixaban compared with gain in life-years suggests that apixaban has a greater impact on the improvement of patient's quality of life than on his or her extension in life-years. The ICER for treatment with apixaban versus warfarin was ¥2,135,743 per QALY (US $21,357 per QALY). Although no specific ICER threshold has been set in Japan, according to Ohkusa et al and Shiroiwa et al, the WTP to gain 1 QALY in Japan is ¥6,700,000 per QALY (US $67,000 per QALY) and ¥5,000,000 (US $50,000 per QALY) per QALY, respectively. 22, 23 On the basis of the reported estimates of the WTP, apixaban is considered cost-effective by a payer's perspective. Other than the payer's perspective, whether this extra cost of apixaban for a marginal benefit from a new treatment is acceptable from a patient's perspective may also be in question. A study by Hori et al reported that patients were willing to pay ¥819 (US $8.2) per day for an alternative drug that does not need monitoring or dietary restrictions, such as warfarin. 24 The daily cost of apixaban is approximately ¥550 (US $5.5) in Japan, out of which the amount that a patient copays is ¥165 (US $1.7) (based on a 30% copayment requirement). Thus, a Japanese patient's copayment amount of apixaban is lower than how much he or she is willing to pay. In the cost-effective analysis, we conducted a oneway sensitivity analysis that identified the risk of ischemic and unspecified stroke associated with the use of apixaban and the risk of ICH associated with the use of warfarin to largely affect the results. We also found that, at the higher at the higher end of the CI, the probability of apixaban being cost-effective with a WTP of ¥5,000,000 yen per QALY (US $50,000 per QALY) and ¥6,700,000 per QALY (US $67,000 per QALY) was 85% and 91%, respectively.
Consistent with the pivotal ARISTOTLE trial, 6 our analysis had warfarin only as the comparator. Studies from other countries have reported that apixaban was cost-effective when compared with other NOACs. 10, 25, 26, 27, 28 Below ICD codes in MDV data (excluding above ischemic stroke, intracranial hemorrhage and systemic embolism) I20-I25 (ischemic heart disease) I26-I28 (pulmonary heart disease and pulmonary circulation disease) I60-I69 (cerebrovascular disease) I70-I79 (artery, arteriole and capillary disease) I80-I89 (vein, lymphatic vessel and lymph node disease, not categorized in other definition) G45 (transient ischemic attack and related syndrome) CRNM ¼ clinically relevant nonmajor bleeding; ICD ¼ International Classification of Diseases; ICH ¼ intracranial hemorrhage; MDV ¼ Medical Data Vision Co Ltd; MI ¼ myocardial infarction; mRS ¼ modified Rankin Scale. * Patients under dialysis or cancer (these patients presents a great impact on the total medical cost).
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET-AF) trial (rivaroxaban 20 mg once daily vs warfarin). 6, 29, 30 The RE-LY trial and ROCKET-AF trial have different patient backgrounds and study designs (the ROCKET-AF trial targets a high-risk population, the RE-LY trial is open label, but the ROCKET-AF and ARISTOTLE trials are double-blind comparative trials), and the study dose of rivaroxaban in the ROCKET-AF trial is different from the Japanese approved dose (15 mg once daily).
In addition, because all these NOACs have the same prices, it would be likely to have no incremental cost between these NOACs in the Japanese setting of clinical practice. Hence, inclusion of the other NOACs was not adapted to comply with the standard approach of cost-effectiveness analysis.
As with all cost studies, our study presents several limitations worth mentioning. First, we did not use Japan-specific utility data except for chronic phase stroke because of a lack of utility data for some event states. 16 In addition, as mentioned above, the utility values of severe stroke in the Japanese model were significantly lower than those in the original model, but the reason for the difference is unknown because of a lack of data, such as a country comparative study using the EQ-5D for stroke. Sakthong et al reported that the difference in utility values of type 2 diabetes mellitus was observed between the preference weights in the United Kingdom, United States, and Japan, revealing higher scores in the United States than in the United Kingdom and Japan. 31 The Japanese researchers Shiroiwa et al also reported that there was a difference between the utility scores for the general population in Japan and the other countries. 32 Those findings, however, come from general or mild health condition of patients. It is conjectured that, specific to countries, the utility scores differ in severe conditions more largely than in mild ones. Therefore, the issue of discrepancy between the Japanese and original utility values in the case of severe stroke is still left for further investigations. However, in our sensitivity analysis, we saw only a small impact resulting from a change in the utility parameters. The highest ICER in the sensitivity analysis on utility parameters was ¥2,763,056 per QALY (US $27,631 per QALY) when the utility decrement of warfarin parameter was set to the least favorable for apixaban, that is, with no utility decrement for warfarin (warfarin disutility of 0). We therefore believe that using utility data from overseas would not significantly reverse our conclusion.
Second, the claims data provided by the MDV, which was used as the data source of the acute-phase cost for each event, were based on the actual treatment data from 131 hospitals. The MDV database represents only a proportion (9%) of the 1496 hospitals that have adopted the DPC system in Japan. On the other hand, the patient compositions listed by the major diagnostic categories in the MDV data are similar to the 2012 Discharged Patient Survey by the Ministry of Health, Labour and Welfare.
15 Therefore, it is reasonable to assume that the MDV claims data are representative of the nationwide composition of hospitalized patients and related costs. Moreover, we found similarities in the literature that support our results. On estimating the acute-phase cost of stroke and MI, Toyonaga et al counted the cost of stroke in 171 patients admitted to several laborer hospitals in 2005 and reported an acute-phase cost of approximately ¥1,300,000 (US $13,000) for ischemic stroke, ¥1,500,000 (US $15,000) for intracerebral hemorrhage, and ¥3,800,000 (US $38,000) for subarachnoid hemorrhage. 33 These costs were similar to our results of ¥1,401,931 (US $14,019) for acute-phase ischemic stroke and ¥1,697,332 (US $16,973) for 19 which is almost the same as the cost for acute-phase MI of ¥2,156,290 (US $21,563) calculated in our analysis.
Despite the limitations we discussed, the impact of these limitations on our results was considered small, and our results were deemed robust because of the additional effect in Japanese patients compared with that in the global population.
In conclusion, based on an adaptation of a published Markov model, apixaban was a cost-effective alternative to warfarin in Japanese NVAF patients by lowering risks of clinical events, such as stroke and bleeding and extending QALYs. Further research extrapolating the cost-effectiveness of apixaban versus warfarin with more representative and larger Japanspecific real-world data or trial-based clinical data, resource utilization, and utility data whenever available would be warranted. Figure 4 . Results of probabilistic sensitivity analysis (cost-effectiveness acceptability curve). The costeffectiveness acceptability curve revealed that when the willingness to pay was approximately Z¥2,250,000 (US $22,500) per quality-adjusted life-year QALY, the probability of apixaban being cost-effectiveness was Z50%. 
